BioPharmSignal logoBioPharmSignal

Biotech News

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology (SANA)Sana BiotechnologyEarnings

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data,

Related news

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

OCGNOcugen2026-07-28 20:01 EST

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

OCGNOcugen2026-04-29 11:02 EST

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

View all latest news

Sana Biotechnology

Engineered Cell Therapies Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies. SC451 Islet-Cell Therapy SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate...

Recent company news

SANASana Biotechnology2026-08-10 20:05 EST

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

SANASana Biotechnology2026-07-13 12:00 EST

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

SANASana Biotechnology2026-05-15 13:00 EST

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Stock data

Close
3.68 USD
Market cap
901.66M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States